

## Media Release

Zug, 29 May 2013

### **Ophthotech secures financing of USD 175 million for phase-III clinical trial of Fovista™**

Ophthotech Corporation, a privately held company in the portfolio of HBM Healthcare Investments, has concluded a USD 175 million financing deal. The funds will be used to conduct a pivotal phase-III clinical study of Ophthotech's lead compound Fovista™. The study is expected to begin in the third quarter of 2013, and will encompass around 1,900 patients across over 200 centres world-wide.

The USD 175 million in financing consists of USD 125 million from the holding company Novo A/S, in exchange for royalties on future sales of Fovista™, and a capital increase of USD 50 million, financed by both Novo A/S and existing Ophthotech shareholders. The overall financing package can be called up by Ophthotech in three equal tranches, the first of which has already been completed.

HBM Healthcare Investments has been invested in Ophthotech since 2007. When this financing round is completed, it will hold approximately 14% of the company. The terms of the financing raise the book value of the investment in Ophthotech to USD 42.1 million. This lifts the net asset value (NAV) per HBM share to CHF 78.23 as at 28 May 2013, which corresponds to an increase of 3.9% compared to the last published NAV as per mid May 2013 or 33% since the beginning of calendar year 2013.

Fovista™ is an anti-PDGF inhibitor which is being tested in combination with an anti-VEGF inhibitor for the treatment of age-related macular degeneration (wet AMD). In June 2012, data from the phase 2b trial in 449 patients showed that those patients who received Fovista™ in combination with the existing drug Lucentis® experienced a 62% greater improvement in visual acuity than patients treated with Lucentis® alone.

Wet AMD is the major cause of age-related blindness. The global market for drugs to treat this condition is currently worth over USD 5 billion and is expanding strongly. The current market is essentially shared by the two anti-VEGF therapies Lucentis® (distributed by Roche and Novartis) and Eylea® (distributed by Regeneron Pharmaceuticals and Bayer).

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

### About Ophthotech

Ophthotech Corporation is a privately held biopharmaceutical company focusing on discovering, developing and commercialising first-in-class therapies for the treatment of major ophthalmic diseases. Ophthotech's lead compound Fovista (previously known as E10030) is being developed for use in combination with anti-VEGF therapy for the treatment of patients with wet AMD. Today, despite the availability of anti-VEGF wet AMD drugs, there remains a significant unmet medical need. The majority of patients treated with anti-VEGF monotherapy, the current standard of care, are unable to achieve significant visual gain, and many of these patients lose additional vision. In addition to Fovista, Ophthotech's pipeline includes an anti-C5 agent, ARC1905, a potent and selective inhibitor of factor C5 of the complement cascade being developed for the treatment of wet and dry AMD. There are more than 15 million patients suffering from dry AMD in just the United States and Europe, and there is no approved therapy. Ophthotech's investors include SV Life Sciences, Novo Ventures, HBM Healthcare Investments and Clarus Ventures. Ophthotech is headquartered in New York, and also has offices in Princeton, NJ. For more information, please visit [www.ophthotech.com](http://www.ophthotech.com).

### About Novo A/S

Novo A/S, a private limited liability company fully owned by the Novo Nordisk Foundation, is the holding company in the Novo Group, and responsible for managing the Foundation's assets, which are currently valued at more than USD 30 billion. In addition to being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science and biotechnology, as well as managing a broad portfolio of financial assets. Novo A/S is an international investor working from Copenhagen, San Francisco and London. Through its teams of scientific and commercial experts, Novo A/S actively supports its portfolio of projects and companies, and manages a range of financial investments.

### Information on HBM Healthcare Investments Ltd.

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes

#### HBM Healthcare Investments Ltd

Bundesplatz 1 | CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com)  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

### Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.